Fosigotifator

Last updated
Fosigotifator
Fosigotifator.svg
Clinical data
Other namesABBV-CLS-7262; Fosigotifator sodium tromethamine
Legal status
Legal status
  • Investigational
Identifiers
  • [(2S)-1,4-Bis[[2-(4-chloro-3-fluorophenoxy)acetyl]amino]-2-bicyclo[2.2.2]octanyl]oxymethyl dihydrogen phosphate
CAS Number
PubChem CID
UNII
KEGG
Chemical and physical data
Formula C25H27Cl2F2N2O9P
Molar mass 639.37 g·mol−1

Fosigotifator is an experimental small-molecule related to ISRIB licensed by Calico from University of California, San Francisco and partnered with AbbVie, which activates activator of the eukaryotic initiation factor eIF2. [1] [2] [3] Abbott and Calico ran clinical trials to determine if the drug can treat amyotrophic lateral sclerosis (ALS) [4] [5] [6] and major depressive disorder. [1] A formulation of fosigotifator, as its monosodium phosphate salt mixed with tromethamine, is known as ABBV-CLS-7262. Fosigotifator has been patented by AbbVie and Calico as a prodrug for modulation of the integrated stress response pathway. [7]

In January 2025 Abbott and Calico announced that the drug had failed a Phase 2/3 trial in ALS; in July 2025 Abbott ended its partnership with Calico. [1]

References

  1. 1 2 3 "Fosigotifator". alzforum.org. 21 Nov 2025. Retrieved 24 November 2025.
  2. ↑ Masson, Gabrielle (13 November 2025). "AbbVie to end Calico collab, lays off researchers: Stat". www.fiercebiotech.com. Retrieved 24 November 2025.
  3. ↑ "Fosigotifator - AbbVie/Calico - AdisInsight". Adisinsight. Retrieved 24 November 2025.
  4. ↑ Arnold, F. J.; Nguyen, A. D.; Bedlack, R. S.; Bennett, C. L.; La Spada, A. R. (1 August 2023). "Intercellular transmission of pathogenic proteins in ALS: Exploring the pathogenic wave". Neurobiology of Disease. 184 106218. doi: 10.1016/j.nbd.2023.106218 . ISSN   0969-9961. PMID   37394036. S2CID   259300396.
  5. ↑ Martinez-Gonzalez, Loreto; Martinez, Ana (1 February 2023). "Emerging clinical investigational drugs for the treatment of amyotrophic lateral sclerosis". Expert Opinion on Investigational Drugs. 32 (2): 141–160. doi:10.1080/13543784.2023.2178416. hdl: 10261/308825 . ISSN   1354-3784. PMID   36762798. S2CID   256738008.
  6. ↑ Cho, William; Jeong, Anna; Malik, Paul; Boiser, Joey; Huang, Xiu; Rosebraugh, Matthew (25 April 2023). "A Phase 1 First-in-human Study to Investigate the Safety, Tolerability and Food Effect of ABBV-CLS-7262 (P6-4.002)". Neurology. 100 (17 Supplement 2): 4188. doi:10.1212/WNL.0000000000203810. ISSN   0028-3878. S2CID   258416815.
  7. ↑ WO 2020077217,"Prodrug Modulators of the Integrated Stress Pathway",published 2020-04-16


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.